Combination of quercetin and Adriamycin effectively suppresses the growth of refractory acute leukemia

Shi,Yingxu; Su,Xiaotian; Cui,Hongwei; Yu,Lei; Du,Hua; Han,Yanqiu

doi:10.3892/ol.2019.10299

Combination of quercetin and Adriamycin effectively suppresses the growth of refractory acute leukemia

Authors:
- Yingxu Shi
- Xiaotian Su
- Hongwei Cui
- Lei Yu
- Hua Du
- Yanqiu Han
View Affiliations

Affiliations: Department of Laboratory Medicine, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia Autonomous Region 010050, P.R. China, Department of Hematology, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia Autonomous Region 010050, P.R. China, Department of Clinical Medical Research Center, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia Autonomous Region 010050, P.R. China, Department of Pharmacy, The Inner Mongolia Autonomous Region Hospital of Traditional Chinese Medicine, Hohhot, Inner Mongolia Autonomous Region 010020, P.R. China, Department of Pathology, Inner Mongolia Medical University, Hohhot, Inner Mongolia Autonomous Region 010030, P.R. China
Published online on: May 2, 2019 https://doi.org/10.3892/ol.2019.10299
Pages: 153-160

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the effect of combined treatment with quercetin and Adriamycin (doxorubicin) on the development of refractory acute leukemia. Primary leukemic cells were isolated from patients with refractory drug‑resistant acute leukemia. The Cell Counting Kit‑8 assay was used to detect the proliferation of cells treated with a range of doses of Adriamycin, quercetin and a combination of the two drugs. Non‑irradiated mice were used to establish a T cell acute lymphoblastic leukemia (T‑ALL) model, which was subsequently treated with Adriamycin, quercetin and a combination of the two drugs. The survival time was recorded, and white and red blood cells and platelets in mouse peripheral blood were counted. Superoxide dismutase (SOD) activity and malondialdehyde (MDA) content of cardiac tissues were measured as indicators of oxidative stress and damage. Proliferation of primary leukemic cells was reduced by Adriamycin depending on the dose (0.06, 0.6 or 6 µg/ml) and treatment duration (24, 48 or 72 h) compared with the vehicle treated group. Co‑treatment with quercetin achieved a similar suppression of leukemic cell proliferation when a lower dose of Adriamycin (0.03, 0.3 or 3 µg/ml) was administered for the same duration. The survival of non‑irradiated mice with T‑ALL was improved by co‑treatment with a high dose of Adriamycin and quercetin compared with either treatment alone. Compared with treatment with Adriamycin alone, the combined treatment with Adriamycin and quercetin significantly enhanced the SOD activity and reduced the MDA content in the heart. Therefore, quercetin may enhance the effects of Adriamycin on refractory acute leukemia.

View Figures

View References

1	Chan KW: Acute lymphoblastic leukemia. Curr Probl Pediatr Adolesc Health Care. 32:40–49. 2002. View Article : Google Scholar : PubMed/NCBI
2	Ma JJ, Chen Y and Yu L: Research progress on drug-resistance of acute lymphoblastic leukemia-review. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 24:261–265. 2016.(In Chinese). PubMed/NCBI
3	Jing H and Feng R: Research progress on minimal residual disease in acute leukemia detected by multiparametric flow cytometry. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 22:847–851. 2014.(In Chinese). PubMed/NCBI
4	Johnson-Arbor K and Dubey R: Doxorubicin. StatPearls. (Treasure Island, FL). 2019.
5	Mehta-Shah N, Ratner L and Horwitz SM: Adult T-cell leukemia/lymphoma. J Oncol Pract. 13:487–492. 2017. View Article : Google Scholar : PubMed/NCBI
6	Ballmann C, Denney T, Beyers RJ, Quindry T, Romero M, Selsby JT and Quindry JC: Long-term dietary quercetin enrichment as a cardioprotective countermeasure in mdx mice. Exp Physiol. 102:635–649. 2017. View Article : Google Scholar : PubMed/NCBI
7	Lipshultz SE, Lipsitz SR, Sallan SE, Dalton VM, Mone SM, Gelber RD and Colan SD: Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol. 23:2629–2636. 2005. View Article : Google Scholar : PubMed/NCBI
8	Padron E and Fernandez H: Anthracycline dose intensification in young adults with acute myeloid leukemia. Ther Adv Hematol. 3:17–27. 2012. View Article : Google Scholar : PubMed/NCBI
9	Li Y, Yao J, Han C, Yang J, Chaudhry MT, Wang S, Liu H and Yin Y: Quercetin, inflammation and immunity. Nutrients. 8:1672016. View Article : Google Scholar : PubMed/NCBI
10	Darband SG, Kaviani M, Yousefi B, Sadighparvar S, Pakdel FG, Attari JA Mohebbi I, Naderi S and Majidinia M: Quercetin: A functional dietary flavonoid with potential chemo-preventive properties in colorectal cancer. J Cell Physiol. 233:6544–6560. 2018. View Article : Google Scholar : PubMed/NCBI
11	Francaux M and Deldicque L: Using polyphenol derivatives to prevent muscle wasting. Curr Opin Clin Nutr Metab Care. 21:159–163. 2018.PubMed/NCBI
12	Han Y, Yu H, Wang J, Ren Y, Su X and Shi Y: Quercetin alleviates myocyte toxic and sensitizes anti-leukemic effect of Adriamycin. Hematology. 20:276–283. 2015. View Article : Google Scholar : PubMed/NCBI
13	Alam RT, Zeid EH and Imam TS: Protective role of quercetin against hematotoxic and immunotoxic effects of furan in rats. Environ Sci Pollut Res Int. 24:3780–3789. 2017. View Article : Google Scholar : PubMed/NCBI
14	Brito AF, Ribeiro M, Abrantes AM, Pires AS, Teixo RJ, Tralhão JG and Botelho MF: Quercetin in cancer treatment, alone or in combination with conventional therapeutics? Curr Med Chem. 22:3025–3039. 2015. View Article : Google Scholar : PubMed/NCBI
15	Lamson DW and Brignall MS: Antioxidants and cancer therapy II: Quick reference guide. Altern Med Rev. 5:152–163. 2000.PubMed/NCBI
16	Chen C, Zhou J and Ji C: Quercetin: A potential drug to reverse multidrug resistance. Life Sci. 87:333–338. 2010. View Article : Google Scholar : PubMed/NCBI
17	Belli JA and Harris JR: Adriamycin resistance and radiation response. Int J Radiat Oncol Biol Phys. 5:1231–1234. 1979. View Article : Google Scholar : PubMed/NCBI
18	Hu X, Shen H, Tian C, Yu H, Zheng G, XuFeng R, Ju Z, Xu J, Wang J and Cheng T: Kinetics of normal hematopoietic stem and progenitor cells in a Notch1-induced leukemia model. Blood. 114:3783–3792. 2009. View Article : Google Scholar : PubMed/NCBI
19	Ma S, Shi Y, Pang Y, Dong F, Cheng H, Hao S, Xu J, Zhu X, Yuan W, Cheng T and Zheng G: Notch1-induced T cell leukemia can be potentiated by microenvironmental cues in the spleen. J Hematol Oncol. 7:712014. View Article : Google Scholar : PubMed/NCBI
20	Garnett MJ and McDermott U: The evolving role of cancer cell line-based screens to define the impact of cancer genomes on drug response. Curr Opin Genet Dev. 24:114–119. 2014. View Article : Google Scholar : PubMed/NCBI
21	Cappetta D, De Angelis A, Sapio L, Prezioso L, Illiano M, Quaini F, Rossi F, Berrino L, Naviglio S and Urbanek K: Oxidative stress and cellular response to doxorubicin: A common factor in the complex milieu of anthracycline cardiotoxicity. Oxidative medicine and cellular longevity. 2017:15210202017. View Article : Google Scholar : PubMed/NCBI
22	Brown PA, Shah B, Fathi A, Wieduwilt M, Advani A, Aoun P, Barta SK, Boyer MW, Bryan T, Burke PW, et al: NCCN Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2017. J Natl Compr Canc Netw. 15:1091–1102. 2017. View Article : Google Scholar : PubMed/NCBI
23	Kim HS, Wannatung T, Lee S, Yang WK, Chung SH, Lim JS, Choe W, Kang I, Kim SS and Ha J: Quercetin enhances hypoxia-mediated apoptosis via direct inhibition of AMPK activity in HCT116 colon cancer. Apoptosis. 17:938–949. 2012. View Article : Google Scholar : PubMed/NCBI
24	Maso V, Calgarotto AK, Franchi GC Jr, Nowill AE, Filho PL, Vassallo J and Saad ST: Multitarget effects of quercetin in leukemia. Cancer Prev Res (Phila). 7:1240–1250. 2014. View Article : Google Scholar : PubMed/NCBI
25	Shen Y, Croft KD, Hodgson JM, Kyle R, Lee IL, Wang Y, Stocker R and Ward NC: Quercetin and its metabolites improve vessel function by inducing eNOS activity via phosphorylation of AMPK. Biochem Pharmacol. 84:1036–1044. 2012. View Article : Google Scholar : PubMed/NCBI
26	Rivina L, Davoren M and Schiestl RH: Radiation-induced myeloid leukemia in murine models. Hum Genomics. 8:132014. View Article : Google Scholar : PubMed/NCBI
27	Almosailleakh M and Schwaller J: Murine models of acute myeloid leukaemia. Int J Mol Sci. 20(pii): E4532019. View Article : Google Scholar : PubMed/NCBI
28	Segredo MP, Salvadori DM, Rocha NS, Moretto FC, Correa CR, Camargo EA, de Almeida DC, Reis RA, Freire CM, Braz MG, et al: Oxidative stress on cardiotoxicity after treatment with single and multiple doses of doxorubicin. Hum Exp Toxicol. 33:748–760. 2014. View Article : Google Scholar : PubMed/NCBI